Fig.6 Application of Cas13b and Cas13d in vivo. (A) The scheme describes the cross strategy of Cas13-Luciferase knock-down mice and luciferase expressing transgenic mice. (B) Luciferase RNA expression of mouse liver. The results are presented as mean ± SD. Data are analyzed by unpaired Student’s t-test *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. (C-D) Luciferase images of male (B) and female (C) dTg (offspring of Cas13b-Luc gRNA KI mating with Luciferase mouse) (n=5). (E) The scheme describes the process of mcherry knock-down in mouse liver. (F-G) The mcherry RNA expression in mouse liver. The results are presented as mean ± SD. Data are analyzed by one-way ANOVA. ****P < 0.0001. (H) Representative flow cytometry profiles and quantification of the frequencies of mcherry positive cell population. (I) The results of immunohistochemistry represent the expression of mcherry protein in mouse liver (n=5). (J) The scheme describes the process of generation of acute hepatic failure model and the gene knock-down strategy of CRISPR/Cas13. (K) Hematoxylin-eosin staining results of mouse liver at 24 hours after injecting D-GalN/LPS (n=5), living or dead indicated the animal state at the sampling time point. (L-M) NF-kB andTNFa RNA expression in mouse liver. The results are presented as mean ± SD. Data are analyzed by one-way ANOVA. ****P < 0.0001.